# Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study

> **NCT04014530** · PHASE1,PHASE2 · RECRUITING · sponsor: **Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)** · enrollment: 47 (estimated)

## Conditions studied

- Colorectal Cancer
- Endometrium Cancer

## Interventions

- **DRUG:** Ataluren + Pembrolizumab

## Key facts

- **NCT ID:** NCT04014530
- **Lead sponsor:** Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-08-01
- **Primary completion:** 2023-06-01
- **Final completion:** 2023-08-01
- **Target enrollment:** 47 (ESTIMATED)
- **Last updated:** 2023-02-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04014530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04014530, "Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04014530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*